Skip to content

Epidaurus · Treatment Guide · Alternative & Complementary Medicine

Going abroad for —

Stem Cell Therapy Availability

Stem cell treatment availability for various conditions

The country comparison

Which countries are best for stem cell therapy availability

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 South Korea KR 5.0/5 Good South Korea meets all criteria for an excellent stem cell therapy destination. The country hosts 30+ facilities serving international patients with a full spectrum of stem cell types (autologous, allogeneic, adipose-d... Full report
    The evidence behind this score 7 cited points
    • 30+ facilities actively treating international stem cell patients across Seoul, particularly concentrated in Gangnam district
    • Full spectrum of stem cell types available: autologous, allogeneic, adipose-derived, bone marrow-derived, and umbilical cord blood stem cells with IV, intrathecal, and intra-articular delivery methods
    • Same-day consultation and procedure mostly possible, with 2-7 day timeline if additional tests required, and no waiting lists unlike the U.S.
    • Dedicated International Patient Departments with comprehensive multilingual support (English, Japanese, Chinese, Korean) and all-inclusive packages covering therapy, accommodation, and airport transfers
    • Extensive treatment coverage including orthopedic (osteoarthritis, Cartistem for knee conditions), neurological (Parkinson's, ALS, stroke), autoimmune (lupus, rheumatoid arthritis, MS), oncological (hematopoietic stem cell transplants with 68% success rate at Samsung Medical Center), and aesthetic applications
    • World-class infrastructure including cord blood banks (KCBB, SCBB), MEDIPOST's CARTISTEM® (world's first regulatory-approved cord blood-derived MSC product), state-of-the-art GMP-certified processing facilities, and major hospital backup (Samsung Medical Center with 1,500+ successful transplants, Asan Medical Center with 20,086+ international patients annually)
    • Established as a global stem cell tourism hub with substantial international patient volumes (Asan 20,086+ annually, BIOFACE 25,000+ annually, Reberry 100,000+ treated)

    Read the full South Korea report →

  2. 2 United Arab Emirates AE 5.0/5 Good The UAE has established itself as an excellent stem cell therapy destination with 22+ facilities across three major cities, a full spectrum of stem cell types and delivery methods, and world-class infrastructure ancho... Full report
    The evidence behind this score 6 cited points
    • 22+ facilities offering stem cell therapies across Dubai, Abu Dhabi, and Al Ain, including flagship ADSCC and DHA-licensed private clinics
    • Full spectrum of stem cell types (autologous, allogeneic, CAR-T, cord blood, iPSCs) and delivery methods (IV, intrathecal, intra-articular, direct injection)
    • Treatment available for both established indications (leukemia, MS, thalassemia) and emerging applications (Parkinson's, spinal cord injury, anti-aging, cosmetic)
    • ADSCC holds FACT-JACIE accreditation (one of two in Middle East), UAE's largest GMP laboratory, CAR-T manufacturing capacity of 200/year, and DoH Centre of Excellence status
    • Dubai Smart Medical Visa (3-5 day approval), universal English, multilingual staff (Russian, Hindi, Chinese), telemedicine, VIP transport, and all-inclusive packages standard
    • 8 AABB/DHA-accredited cord blood banking facilities supporting therapeutic supply chain

    Read the full United Arab Emirates report →

  3. 3 Colombia CO 5.0/5 Good Colombia meets all Score 5 criteria with 23+ facilities across six cities offering a comprehensive spectrum of stem cell types (autologous, allogeneic, HSCT) and delivery methods (IV, intra-articular, intrathecal, dir... Full report
    The evidence behind this score 6 cited points
    • 23 facilities on Bookimed with 10+ certified in Medellín alone; six-city geographic distribution (Medellín, Bogotá, Cali, Pereira, Cartagena, Barranquilla)
    • Full spectrum of stem cell types available: umbilical cord Wharton's Jelly MSCs, autologous adipose/bone marrow MSCs, and HSCT; multiple delivery methods including IV, intra-articular, intrathecal, direct injection
    • Comprehensive condition coverage: orthopedic, neurological (MS, Parkinson's, spinal cord injury, stroke), autoimmune (lupus, rheumatoid arthritis, Crohn's disease), metabolic (diabetes), hematological/oncological indications, and anti-aging/wellness applications
    • Wait times days to weeks with 48-hour response at Stemwell; visa-free entry for 90+ nations; English-speaking staff standard; all-inclusive packages with accommodation, airport transfer, telemedicine follow-up (3–19 months)
    • GMP-certified on-site labs (BioXcellerator, Alevy, Regencord), AABB-approved biobanking (America Cell Bank), JCI-accredited hospitals (Fundación Valle del Lili ranked 162nd globally, Hospital Internacional de Colombia with Mayo Clinic partnership)
    • $235 million medical tourism sector; 85,000 international patients in 2023; 23,323 in Medellín in 2024; established marketing through PlacidWay, Bookimed, Medical Tourism Association

    Read the full Colombia report →

  4. 4 Malaysia MY 5.0/5 Good Malaysia demonstrates exceptional stem cell therapy availability for international patients, with 48-49 clinics plus 13 government-authorized HSCT hospitals offering a comprehensive spectrum of stem cell types (autolo... Full report
    The evidence behind this score 5 cited points
    • 48-49 stem cell clinics in medical tourism directories plus 13 government-authorized HSCT hospitals offering international patient access across Kuala Lumpur, Penang, Johor Bahru, and multiple additional cities
    • Full spectrum of stem cell modalities: autologous MSCs (bone marrow, adipose), allogeneic cord blood-derived MSCs, NK cell therapy, exosome therapy, and gene therapies with multiple delivery methods
    • Comprehensive condition treatment range spanning orthopedic, neurological (including autism with specific international marketing), autoimmune, metabolic, anti-aging, and established hematological indications
    • Wait times of 1-2 weeks typical for private regenerative clinics with standard telemedicine pre-consultations and all-inclusive packages at USD 9,800-21,700 including accommodation and transport
    • World-class supporting infrastructure: AABB-accredited cord blood banks operating 20+ years (CryoCord, StemLife), cGMP-certified processing facilities, national stem cell registry of 31,200 donors, and Hospital Ampang performing 180+ HSCT transplants annually

    Read the full Malaysia report →

  5. 5 Mexico MX 5.0/5 Good Mexico meets and exceeds all Score 5 criteria for stem cell therapy availability. The country has 76+ confirmed physical locations nationally (with 110+ clinic websites in Tijuana alone), multi-location networks, and ... Full report
    The evidence behind this score 8 cited points
    • 76 confirmed physical stem cell clinic locations in Tijuana alone, with 110 unique clinic websites identified in a 2021 peer-reviewed study (Chavez et al., Stem Cell Research & Therapy)
    • Medical Tourism Review Board lists at least 22 notable clinics nationally; clinics distributed across 9+ geographic regions (Tijuana, Cancun, Puerto Vallarta, Mexico City, Guadalajara, Monterrey, Los Cabos, Los Algodones, Ajijic)
    • Comprehensive stem cell types available: autologous (bone marrow, adipose) and allogeneic (umbilical cord MSCs, placental), with fresh (99% viability) and cryopreserved (94% viability) options
    • Full spectrum of delivery methods including IV infusion, intrathecal injection, intra-articular, intramuscular, intradermal, intranasal, and nebulizer delivery with multi-route protocols standard
    • Wait times minimal: consultations scheduled within 24-48 hours, full treatment protocols completed within 1-3 days (far exceeding Score 5 requirement of under 2 weeks)
    • Comprehensive medical tourism infrastructure standard: bilingual staff, airport pickup, border crossing assistance, no visa requirements for US/Canadian citizens, dedicated patient coordinators, telemedicine consultations
    • Mexico ranks among top 5 countries globally for stem cell tourism; R3 Stem Cell reports 27,000+ procedures in 12 years; Giostar Cancun treats ~5,000 patients annually
    • Mexico's stem cell market growing at 12.7% CAGR, projected to reach $369.8 million by 2030, indicating expanding facility network and treatment accessibility

    Read the full Mexico report →

  6. 6 Thailand TH 5.0/5 Good Thailand exhibits excellent stem cell therapy availability with a mature, international-focused infrastructure. The country supports 10+ dedicated clinics plus extensive hospital networks (62 JCI-accredited organizati... Full report
    The evidence behind this score 7 cited points
    • More than 10 dedicated stem cell clinics plus major hospital networks (e.g., Bangkok Hospital's 53 locations with 14 JCI-accredited; 62 JCI-accredited organizations nationally) actively treating international patients
    • Full spectrum of stem cell types available: UC-MSCs, adipose-derived, bone marrow-derived, placental, amniotic sources with multiple delivery methods (IV, intrathecal, intra-articular, direct injection)
    • Comprehensive condition coverage: orthopedic (osteoarthritis, degenerative disc disease), neurological (Parkinson's, ALS, autism, MS, stroke recovery), autoimmune (lupus, RA, Crohn's), anti-aging/wellness, and established oncology with 92% one-year survival rate
    • Excellent accessibility: wait times days to 2-4 weeks (under 2-week threshold), standard programs 5-14 days, multilingual staff (English, Arabic, Chinese, Russian, Spanish), telemedicine consultations, visa assistance, all-inclusive packages with accommodation and airport transfers
    • Geographic distribution across multiple major cities: Bangkok (primary hub with multiple major facilities), Phuket (high-end clinics), Chiang Mai (holistic programs), Pattaya
    • Strong infrastructure: GMP-certified laboratories (The Regeneration Center's four GMP-approved facilities, Thai FDA-licensed SC21 Bio-Pharma), AABB-accredited cord blood banking (Cryoviva, THAI StemLife), established cell banking services
    • Thailand recognized as one of the top five global stem cell tourism destinations; medical tourism market projected at USD 3.27 billion by 2033; Bumrungrad serves 1.1 million patients annually from 190 countries

    Read the full Thailand report →

  7. 7 Turkey TR 4.5/5 Good Turkey demonstrates excellent stem cell therapy availability for international patients, with 33–35 confirmed facilities offering a full spectrum of treatments (HSCT, CAR-T, CAR-NK, MSC-based therapies) across 50+ med... Full report
    The evidence behind this score 10 cited points
    • 33–35 facilities actively treating international stem cell patients per curated directories (mespoir.com, MediGlobus); 424 clinics in Bookimed database
    • Full spectrum of treatments: autologous/allogeneic HSCT, CAR-T, CAR-NK, MSCs from umbilical cord/adipose/bone marrow; delivery via IV, intrathecal, intranasal, intra-articular
    • 50+ conditions treated: hematological (AML, ALL, lymphoma), orthopedic (osteoarthritis, degenerative disc), neurological (MS, ALS, Parkinson's, autism, stroke), autoimmune, anti-aging, cosmetic
    • Wait times: days to 2 weeks for private MSC clinics; expedited processing for international HSCT patients
    • Multilingual support (English, Arabic, German, Russian), free virtual consultations, all-inclusive travel packages, telemedicine pre/post-treatment standard
    • GMP infrastructure: Liv Hospital hospital-based GMP center (first in Turkey), TurkeyStemcell ISO/GMP facility, Ministry-approved GMP center active since 2014
    • Cord blood banks: GenKord established 2003, Onkim established 2006
    • Geographic distribution: primary hub in Istanbul; secondary nodes in Ankara, Antalya, Bursa, Izmir, Mugla
    • Market position: ranked third globally on Bookimed for stem cell tourism; 2 million health tourists in 2024 ($3 billion revenue); stem cell therapy identified as fastest-growing category; 50% of R3 Stem Cell patients are repeat visitors or European referrals
    • Regulatory concern: 2018 Ministry of Health Stem Cell Circular restricts non-hematopoietic therapies to research; minimal enforcement creates grey zone

    Read the full Turkey report →

  8. 8 Israel IL 4.5/5 Good Israel demonstrates exceptional stem cell therapy availability with comprehensive treatment options, robust infrastructure, and global standing as an established stem cell tourism hub. While the facility count of 13+ ... Full report
    The evidence behind this score 5 cited points
    • 13+ facilities offering stem cell therapy to international patients across multiple major cities (Tel Aviv, Jerusalem, Haifa) with geographic distribution across the country, exceeding Score 4 threshold
    • Full spectrum of stem cell types and delivery methods available: autologous and allogeneic HSCT, CAR-T cell therapy, MSC from adipose/bone marrow/cord blood/placental sources, with IV, intrathecal, intra-articular, and direct tissue injection options
    • Exceptional accessibility with 1-2 week wait times from inquiry to treatment in private sector, multilingual support (English standard plus Russian, Arabic, French, Spanish, Mandarin), telemedicine pre/post-treatment consultations, and dedicated international patient departments at all major hospitals
    • World-leading infrastructure: Sheba Medical Center is Europe's largest CAR-T therapy center (258+ patients treated), combined national HSCT volume exceeds 600 transplants annually, national public cord blood bank integrated with NMDP international registry, multiple JCI-accredited institutions with GMP-certified cell processing
    • Recognized as global stem cell tourism hub with established research innovation ecosystem (Hebrew University, Tel Aviv University, Weizmann Institute) driving clinical access and continuous protocol development

    Read the full Israel report →

  9. 9 Japan JP 4.5/5 Good Japan demonstrates comprehensive stem cell therapy availability with 15–20+ certified private clinics in Tokyo and Osaka actively treating international patients, world-class GMP-equivalent infrastructure mandated by ... Full report
    The evidence behind this score 6 cited points
    • Facility count: 15–20 private clinics in Tokyo plus additional facilities in Osaka (Cell Grand Clinic) and academic centers (University of Tokyo Hospital, National Cancer Center) actively accepting international patients
    • Treatment range: Autologous adipose-derived MSCs (100–300 million cells per infusion), world-first iPSC therapies approved 2026 (Amchepry for Parkinson's, ReHeart for heart failure), NK cell therapy, SVF therapy, with IV, intra-articular, intrathecal, and direct injection delivery methods
    • Condition coverage: Orthopedic (osteoarthritis, degenerative disc disease, sports injuries), metabolic (diabetes, arteriosclerosis), neurological (stroke, spinal cord injury, dementia, Parkinson's), anti-aging/wellness, cosmetic (hair loss, skin rejuvenation), and oncology support
    • Accessibility: Wait times 4–6 weeks (two-visit protocol with 4–6 week expansion period) or expedited 3–5 day protocols; strong multilingual support at major clinics (16+ English speakers at Omotesando; English, Arabic, Russian, Mandarin at Rakan); medical visa facilitation, airport transfers, hotel partnerships, telemedicine pre/post consultation standard
    • Infrastructure: ASRM law mandates GMP-equivalent cell processing and safety committee review; 2,235+ registered cell processing facilities nationwide; StemCell Institute (Japan's largest cord blood bank, 60,000+ samples); 25 JCI-accredited hospitals; Takara Bio GMP facility expansion
    • Market position: World-leading regulatory framework, active international marketing through Medical Excellence JAPAN (MEJ), established patient testimonials (150+ reviews on PlacidWay for Cell Grand Clinic), Nobel Prize lineage in iPS research (Shinya Yamanaka, 2012)

    Read the full Japan report →

  10. 10 Poland PL 4.0/5 Good Poland demonstrates solid stem cell therapy availability with 10–12 facilities actively treating international patients across multiple cities, offering a good range of stem cell types (autologous adipose MSCs, alloge... Full report
    The evidence behind this score 6 cited points
    • 10–12 clinics and hospitals offering stem cell therapy to international patients across six major Polish cities (Warsaw, Kraków, Wrocław, Jelenia Góra, Rzeszów, Głogów)
    • Multiple stem cell types available: autologous adipose-derived MSCs, allogeneic Wharton's jelly MSCs, bone marrow-derived HSCs, and cord blood HSCs with IV, intrathecal, and intra-articular delivery methods
    • Good condition coverage: orthopedic (most widely available), neurological (autism, ALS, MS, spinal cord injury), hematological/oncological (leukemia, lymphoma, bone marrow failure), and metabolic applications
    • 2–4 week wait times for orthopedic protocols at private clinics; English-speaking staff, telemedicine, and all-inclusive packages at leading facilities (Carolina Medical Center, KCM Clinic, NOVACELL)
    • Strong infrastructure: PBKM is Europe's largest AABB-accredited, GMP-certified cord blood bank and processing laboratory; Poland's bone marrow donor registry is world's fourth largest
    • 2023 regulatory reform constrains experimental ATMP-HE neurological programs by prohibiting direct patient fees, reducing previous availability in this segment

    Read the full Poland report →

  11. 11 Spain ES 4.0/5 Good Spain presents a well-developed stem cell therapy landscape with 15–20 facilities actively treating international patients, strong infrastructure (TERAV's 14 GMP-certified production facilities, 9 public cord blood ba... Full report
    The evidence behind this score 7 cited points
    • 15–20 facilities actively treating international stem cell patients, spanning Quirónsalud network, academic centers (Barnaclínic+, Hospital Clínic, Clínica Universidad de Navarra), and private clinics across Barcelona, Madrid, Pamplona, Málaga, Alicante, Valencia, and Ibiza
    • Multiple stem cell types available: autologous and allogeneic HSCT, autologous adipose-derived MSCs, cultured MSCs, CAR-T cell therapy; diverse delivery methods (IV, intra-articular, intrathecal)
    • Established indications widely available: HSCT for blood cancers and select autoimmune diseases (3,717 procedures in 2023); orthopedic MSC therapies at multiple accredited centers
    • Experimental treatments for neurological (ALS, Parkinson's), autoimmune, and anti-aging indications 'almost exclusively restricted to formal clinical trials' with waiting lists of several months to over a year
    • Strong medical tourism infrastructure: JCI-accredited centers with multilingual coordinators (English, Russian, Arabic, French), telemedicine consultations, visa support, and accommodation assistance standard
    • Excellent infrastructure: TERAV network with 14 AEMPS-authorized GMP production facilities; 9 public cord blood banks; REDMO donor registry with ~493,000 registered donors
    • Typical wait times 4–5 weeks for HSCT (Barnaclínic+) and orthopedic procedures, exceeding Score 5 threshold of <2 weeks

    Read the full Spain report →

  12. 12 India IN 4.0/5 Good India demonstrates good availability of stem cell therapies for medical tourists with substantial facility infrastructure (Apollo Hospitals' 50+ hospitals in major cities plus Max Healthcare's 8 Delhi hubs and numerou... Full report
    The evidence behind this score 5 cited points
    • Apollo Hospitals operates over 50 facilities in major Indian cities with Max Healthcare operating 8 medical hubs in New Delhi; NeuroGen BSI has treated 6,000+ patients from 60+ countries; R3 Stem Cell performed 25,000+ procedures in past decade
    • Multiple stem cell types available (autologous, allogeneic, syngeneic transplants); cell sources include bone marrow, adipose tissue, umbilical cord blood; delivery methods include intravenous, intrathecal, and stereotactic injection; labs are GMP/GTP certified and DCGI-approved
    • Treatment possible within days of arrival; facilities offer medical visas (typically 6 months), transport, hotel booking, visa assistance, and language interpretation; telemedicine consultations available for pre- and post-treatment coordination
    • Comprehensive condition coverage spanning neurological (Parkinson's, MS, spinal cord injury), orthopedic (osteoarthritis, joint repair), hematologic (leukemia, lymphoma, myeloma), and emerging applications (anti-aging, autoimmune disorders)
    • Report documents regulatory gaps with clinics operating in regulation vacuums or loopholes; variable quality among private clinics; limited published outcome data and transparency; centers offer both established hematopoietic transplants (1,500+ for blood cancers) and experimental therapies with limited evidence

    Read the full India report →

  13. 13 United Kingdom GB 3.5/5 Moderate The UK has strong infrastructure and facility density for established stem cell indications (HSCT, MS AHSCT) with multiple JACIE-accredited centers, good wait times (2-4 weeks), and universal English support. However,... Full report
    The evidence behind this score 7 cited points
    • 106 commercial facilities plus multiple JACIE-accredited NHS/private hospitals, but Bookimed lists only 1 as active international partner
    • World-class HSCT infrastructure: King's College Hospital 200+ transplants annually, UCLH largest transplant centre in Europe, London Clinic largest accredited stem cell collection centre in Europe (700+ donations/year); London Bridge Hospital 10-year track record in AHSCT for MS with 70-80% NEDA remission rates
    • Regulatory bottleneck: MHRA requires clinical trial authorisation or full ATMP marketing approval for expanded/allogeneic therapies; 'permissive range of treatments available in Panama, Thailand, or Mexico is simply not on offer' in UK
    • UK is patient exporter: 348,000 UK residents travelled abroad for medical treatment in 2022 including stem cell therapy; UK citizens seek cheaper options in Turkey, Spain, Serbia (40-50% cost reduction); MS Society UK notes patients travel to Russia, Poland, Mexico for HSCT outside NHS criteria
    • Minimal medical tourism infrastructure: no all-inclusive packages, no visa facilitation, no dedicated travel coordination; high costs (£4,000-£12,000 orthopedic; £30,000+ AHSCT) vs competitors
    • Quality concerns: 79% of UK commercial stem cell clinics assessed as problematic in marketing with missing adverse effect disclosure and unjustifiably optimistic efficacy claims
    • Extreme geographic concentration: 28 facilities in London West End, 15 on Harley Street; absent from major tourism destination rankings (Bookimed, Medical Tourism Association, Medical Tourism Magazine)

    Read the full United Kingdom report →

  14. 14 Singapore SG 3.5/5 Moderate Singapore operates 6 formal HSCT facilities with world-class infrastructure (ACTRIS GMP manufacturing, accredited cord blood banks) and excellent international patient services, placing it above typical Score 3 on acc... Full report
    The evidence behind this score 5 cited points
    • 6 major hospitals performing HSCT (SGH, NCIS, NCCS, Mount Elizabeth, Gleneagles, Parkway Cancer Centre), below Score 4 threshold of 10-19 facilities
    • Regulatory prohibition: MOH explicitly prohibits anti-aging, neurological, cosmetic, and systemic MSC therapies outside clinical trials; only 4 categories of treatment permitted
    • Multiple stem cell modalities available for approved indications: autologous, allogeneic, haploidentical, cord blood HSCT, CAR-T therapies (Kymriah, Yescarta)
    • Excellent infrastructure: ACTRIS facility with 14 GMP clean suites (opened 2023), Singapore Cord Blood Bank (CAP/FACT-NetCord accredited, WMDA member, 320+ transplants)
    • Superior accessibility for blood cancer patients: 3-4 week donor matching timelines, comprehensive English-language international patient departments, visa support, telemedicine; but functionally unavailable for 70% of stem cell tourism applications

    Read the full Singapore report →

  15. 15 Hungary HU 3.5/5 Moderate Hungary demonstrates meaningful clinical substance with 8-11 facilities offering diverse stem cell modalities (autologous/allogeneic HSCT, adipose-derived MSCs, BMC, cord blood) and good condition coverage across hema... Full report
    The evidence behind this score 10 cited points
    • 8-11 total facilities including 3 academic HSCT centers (Semmelweis, Debrecen, South Pest Centrum) and 5-8 private clinics, almost entirely in Budapest
    • Multiple stem cell types available: autologous/allogeneic HSCT, FDA-cleared Lipogems adipose-derived MSCs, bone marrow concentrate, cord blood banking; delivery methods include IV infusion, intra-articular injection, intrathecal injection
    • Good range of conditions treated: blood cancers (AML, ALL, lymphomas, MDS, multiple myeloma), MS via AHSCT, orthopedic applications (osteoarthritis, disc degeneration, tendon injuries), and cosmetic applications (hair restoration, facial rejuvenation)
    • Wait times at private orthopedic clinics estimated at 1-3 weeks, better than Score 4 standard of 2-4 weeks
    • English-speaking staff and shuttle services at Mona Lisa Centrum; bilingual Hungarian/English website and contact at Fájdalomklinika
    • Strong academic HSCT infrastructure: Debrecen department has performed ~1,200 transplants since 2003 and operates world-class cell processing equipment; both Debrecen and Semmelweis are EBMT-affiliated centers
    • Outstanding cord blood banking: KRIO Institute AABB-accredited with 32,000+ stored samples, recognized as best performer in FamiCord Group 2025; Cord Blood Center Budapest provides additional accredited option
    • EU ATMP regulatory framework and FDA-cleared Lipogems technology provide standardized quality assurance
    • Major international clinic aggregators (MyMediTravel, MediJump) list no or very limited Hungarian stem cell clinics, indicating limited systematic medical tourism infrastructure engagement
    • Marketing-reality gap identified: references to 'Hungarian Stem Cell Center' and 'Budapest Regenerative Medicine Institute' lack independently verifiable clinical profiles

    Read the full Hungary report →

  16. 16 Brazil BR 3.5/5 Moderate Brazil has significant infrastructure with 10-15 identifiable facilities including R3 Stem Cell International operating across 11 cities, comprehensive stem cell types and delivery methods, broad condition coverage (o... Full report
    The evidence behind this score 5 cited points
    • R3 Stem Cell International operates Centers of Excellence in 11 cities with good geographic distribution across all macro-regions; additional named providers (Center for Cellular Therapy, Institute of Cell Therapy, Regenesis Clinic) bring total to 10-15 facilities
    • Multiple stem cell types available (autologous adipose-derived, allogeneic umbilical cord-derived, bone marrow-derived) with comprehensive delivery methods (IV, intra-articular, intrathecal, intranasal, nebulizer); 70+ conditions nominally treatable
    • Wait times exceptionally short—5-7 day stay typical with same-day procedures available at private clinics; well under 2-week threshold
    • Significant language barriers and inconsistent English support: primarily Portuguese-speaking medical environment requiring facilitator coordination; Brazilian patients themselves travel to Mexico, Colombia, Turkey for stem cell treatment
    • Not recognized as top stem cell tourism destination—absent from major academic reviews and consumer guides for international stem cell therapy; Brazil positioned as net exporter rather than importer of stem cell patients

    Read the full Brazil report →

  17. 17 Germany DE 3.5/5 Moderate Germany offers comprehensive stem cell therapy with exceptional infrastructure and accessibility (48-hour wait times, full spectrum of modalities, 80+ disease categories), positioning it above moderate availability. H... Full report
    The evidence behind this score 7 cited points
    • 5–10 private clinics plus multiple academic HSCT centers; Frankfurt/Rhine-Main cluster dominates
    • Full spectrum of stem cell types (autologous/allogeneic HSC, MSC, SVF, BMC, Secretome) with multiple delivery methods
    • Over 80 disease categories treated; both established (hematological malignancies) and emerging (neurological, orthopedic) applications widely available
    • Rapid wait times: 48-hour appointments for outpatient procedures, 3–4 day total stays for SVF/BMC
    • Comprehensive international infrastructure: 24/7 multilingual coordinators, telemedicine, visa facilitation, airport transfers; English widely supported
    • World-class infrastructure: GMP-certified labs, DKMS cryobank (10.5M donors, world-first), ZKRD registry, José Carreras Cord Blood Bank
    • Positioned as 'leading European destination for scientifically supervised experimental stem cell therapy' but explicitly 'not dominant global destination'; modest international patient volumes for regenerative indications

    Read the full Germany report →

  18. 18 Jordan JO 3.0/5 Moderate Jordan maintains a credible but geographically narrow stem cell therapy ecosystem anchored by KHCC's Eastern Mediterranean-leading bone marrow transplantation program and the University of Jordan's research-driven CTC... Full report
    The evidence behind this score 5 cited points
    • Approximately 6-7 facilities offering stem cell treatments: KHCC, University of Jordan CTC, Specialty Hospital, Arab Medical Centre, Queen Rania AL-Abdullah Children Hospital, Stem Cells Arabia, and Al Khalidi Medical Center—all in Amman
    • KHCC performs approximately 250 bone marrow and stem cell transplants annually with CAP-certified CTAG laboratory offering autologous, allogeneic (related, mismatched, haploidentical), and unrelated cord blood transplants; EBMTR membership provides international donor access
    • Multiple conditions treated: haematological malignancies and blood disorders as primary focus; research protocols for MS, autism, knee cartilage repair, diabetic foot ulcers, and corneal ulcers through University of Jordan CTC
    • Wait times characterized as longer than competing destinations such as Turkey, with no precise weeks published; experimental MSC applications follow research protocol enrolment timelines
    • Good international patient infrastructure including KHCC International Patient Affairs office, English-speaking staff at major hospitals, visa-on-arrival access for most nationalities, and KHCC telemedicine capabilities; however, all-inclusive packages not standard

    Read the full Jordan report →

  19. 19 United States US 2.5/5 Moderate The US has abundant clinic infrastructure (2,754 facilities) spread across multiple cities, but these are largely unproven and unregulated with minimal FDA-approved options beyond specific hematological conditions. Cr... Full report
    The evidence behind this score 5 cited points
    • 2,754 clinics across US but primarily serve domestic patients, not actively promoting international medical tourism
    • Only blood-forming stem cells from umbilical cord blood are FDA-approved; no FDA approval for orthopedic or neurological stem cell treatments marketed by clinics
    • US prices ($20,000-$50,000 per treatment) significantly higher than international alternatives ($8,000-$20,000 in Latin America)
    • Report explicitly states: 'For international patients, the high cost combined with regulatory uncertainty makes the U.S. less attractive than destinations like Mexico, Costa Rica, or Colombia for experimental stem cell treatments'
    • US is increasingly source of outbound medical tourism rather than inbound destination for stem cell therapy; patients leaving the country

    Read the full United States report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for stem cell therapy availability, top to bottom. How we score →

  1. 5/5 Excellent

    - **Facility count**: 20+ facilities actively treating international stem cell patients - **Treatment range**: Full spectrum of stem cell types (autologous, allogeneic, cord blood, adipose) and delivery methods - **Condition coverage**: Both established medical indications and emerging/experimental applications widely available - **Accessibility**: Wait times under 2 weeks, comprehensive medical tourism infrastructure, multilingual support standard - **Geographic spread**: Multiple major cities with quality options - **Infrastructure**: GMP-certified labs, stem cell banking facilities, robust hospital backup - **Examples**: Countries known as global stem cell tourism hubs with established infrastructure

  2. 4/5 Good

    - **Facility count**: 10-19 facilities treating international patients - **Treatment range**: Multiple stem cell types available, most common delivery methods offered - **Condition coverage**: Good range of conditions treated, though some specializations may be limited - **Accessibility**: Wait times 2-4 weeks, good medical tourism support services, English commonly available - **Geographic spread**: Concentrated in 2-3 major cities - **Infrastructure**: Adequate lab facilities, some cell banking capability - **Examples**: Emerging stem cell destinations with growing reputation

  3. 3/5 Moderate

    - **Facility count**: 5-9 facilities accepting international patients - **Treatment range**: Limited to 1-2 stem cell types, basic delivery methods - **Condition coverage**: Focused on specific conditions (e.g., orthopedic only or oncology only) - **Accessibility**: Wait times 4-8 weeks, basic international patient services, language barriers possible - **Geographic spread**: Concentrated in capital city or single region - **Infrastructure**: Basic laboratory capabilities, limited banking - **Examples**: Countries with developing stem cell tourism sectors

  4. 2/5 Poor

    - **Facility count**: 2-4 facilities, limited international patient capacity - **Treatment range**: Very limited stem cell options, often only autologous - **Condition coverage**: Narrow focus, few conditions treated - **Accessibility**: Wait times over 8 weeks, minimal tourism infrastructure, significant language barriers - **Geographic spread**: Very limited, often single facility - **Infrastructure**: Minimal specialized infrastructure - **Examples**: Countries with nascent or struggling stem cell sectors

  5. 1/5 Very Poor / Unavailable

    - **Facility count**: 0-1 facilities, no meaningful international patient access - **Treatment range**: Essentially unavailable or extremely limited to bone marrow transplants only - **Condition coverage**: Only standard hematological/oncological indications if any - **Accessibility**: No medical tourism infrastructure for stem cells - **Examples**: Countries where stem cell therapy is prohibited, unavailable, or impractical for medical tourists

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source adscc.ae/abu-dhabi-manufactures-uaes-first-car-t-cell-to-treat-young-leukemia-patient Cited in Stem Cell Therapy Availability in United Arab Emirates
  2. Untitled source adscc.ae/who-we-are Cited in Stem Cell Therapy Availability in United Arab Emirates
  3. Untitled source alliancerm.org/available-products Cited in Stem Cell Therapy Availability in United States
  4. Untitled source alttreatment.io/2025/08/19/does-turkey-have-stem-cell-therapy-in-2025 Cited in Stem Cell Therapy Availability in Turkey
  5. Untitled source amedical.az/en/blogs/treatments-turkey/stem-cell Cited in Stem Cell Therapy Availability in Turkey
  6. Untitled source ameracell.com Cited in Stem Cell Therapy Availability in United States
  7. Untitled source appliedstemcell.com/about-us/facility Cited in Stem Cell Therapy Availability in United States
  8. Untitled source appliedstemcell.com/ipsc-cgmp-manufacturing Cited in Stem Cell Therapy Availability in United States
  9. Untitled source atlantamedicine.com/treatments/stem-cell-treatments Cited in Stem Cell Therapy Availability in United States
  10. Untitled source bioinformant.com/stem-cell-clinics Cited in Stem Cell Therapy Availability in United States
  11. Untitled source bioinformant.com/u-s-fda-approved-cell-and-gene-therapies Cited in Stem Cell Therapy Availability in United States
  12. Untitled source bioinformant.com/us-cord-blood-banks Cited in Stem Cell Therapy Availability in United States
  13. Untitled source bloodstemcell.hrsa.gov/donor-information/cord-blood-units-research Cited in Stem Cell Therapy Availability in United States
  14. Untitled source boneandjoint.org.uk/Article/10.1302/0301-620X.102B2.BJJ-2019-1104.R1 Cited in Stem Cell Therapy Availability in United States
  15. Untitled source celebrationstemcellcentre.com Cited in Stem Cell Therapy Availability in United States
  16. Untitled source ckmstemcells.com Cited in Stem Cell Therapy Availability in Mexico
  17. Untitled source cryoviva.com/en Cited in Stem Cell Therapy Availability in Thailand
  18. Untitled source doctor.webmd.com/providers/procedure/stem-cell-therapy Cited in Stem Cell Therapy Availability in United States
  19. Untitled source drstemcellsthailand.com/thai-fda-and-stem-cell-regulations-in-thailand Cited in Stem Cell Therapy Availability in Thailand
  20. Untitled source elclinics.com/news/clinics/15-best-stem-cell-therapy-clinics-in-the-world Cited in Stem Cell Therapy Availability in United States
  21. Untitled source en.medi-post.co.kr/celltree Cited in Stem Cell Therapy Availability in South Korea
  22. Untitled source en.wikipedia.org/wiki/Cord_blood_bank Cited in Stem Cell Therapy Availability in United States
  23. Untitled source en.wikipedia.org/wiki/Stem_cell_laws_and_policy_in_the_United_States Cited in Stem Cell Therapy Availability in United States
  24. Untitled source eng.jeunexclinic.com/stem-cell-therapy-korea Cited in Stem Cell Therapy Availability in South Korea

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Alternative & Complementary Medicine

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Stem Cell Therapy Availability

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison